0ME Stock Chart & Stats
€79.70
-€1.16(-1.43%)
At close: 4:00 PM EDT
€79.70
-€1.16(-1.43%)
Day’s Range― - ―
52-Week Range€20.36 - €126.65
Previous CloseN/A
Volume5.00
Average Volume (3M)40.00
Market Cap
€7.94B
Enterprise Value€6.35K
Total Cash (Recent Filing)€166.84M
Total Debt (Recent Filing)€93.59M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 13, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding65,832,420
10 Day Avg. Volume53
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.56
Price to Sales (P/S)4.47
P/FCF Ratio-22.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€95.90Price Target Upside20.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.79
Revenue Forecast (FY)€390.34M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Margin ExpansionSustained double-digit growth alongside improving gross margins indicates rising product adoption and better economics. Continued revenue scale can increase operating leverage and support Twist’s longer-term path toward profitability.
Manufacturing Efficiency And CapacityThese operational improvements strengthen Twist’s competitive position by lowering unit costs, increasing throughput, and improving customer service. Greater capacity and efficiency should support scalable growth while helping sustain or expand gross margins.
AI-Enabled Protein Design PositioningThe engagement validates Twist’s role in connecting computational protein design with laboratory production and testing. As AI-driven discovery expands, this capability may create recurring demand from developers needing high-throughput biological validation.
Bears Say
Persistent Losses And Cash BurnTwist remains dependent on external funding while its operations consume cash and generate substantial losses. Until revenue growth converts into durable positive operating cash flow, financial flexibility and shareholder returns remain constrained.
High Operating Expenses Delay ProfitabilityElevated spending continues to offset gross-profit gains, leaving EBITDA breakeven dependent on future cost reductions and execution. Any delay in achieving operating leverage could extend losses and increase the need for additional capital.
Competitive Pricing And Mix PressureCompetition and discounting could pressure average selling prices and shift demand toward lower-margin products or services. This risk may limit the company’s ability to translate technological differentiation and volume growth into sustained margin expansion.
Twist Bioscience News
0ME FAQ
What was Twist Bioscience Corp’s price range in the past 12 months?
Twist Bioscience Corp lowest stock price was €20.36 and its highest was €126.65 in the past 12 months.
What is Twist Bioscience Corp’s market cap?
Twist Bioscience Corp’s market cap is €7.94B.
When is Twist Bioscience Corp’s upcoming earnings report date?
Twist Bioscience Corp’s upcoming earnings report date is Nov 13, 2026 which is in 79 days.
How were Twist Bioscience Corp’s earnings last quarter?
Twist Bioscience Corp released its earnings results on Aug 03, 2026. The company reported -€0.485 earnings per share for the quarter, missing the consensus estimate of -€0.438 by -€0.047.
Is Twist Bioscience Corp overvalued?
According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued.
Does Twist Bioscience Corp pay dividends?
Twist Bioscience Corp does not currently pay dividends.
What is Twist Bioscience Corp’s EPS estimate?
Twist Bioscience Corp’s EPS estimate is -0.34.
How many shares outstanding does Twist Bioscience Corp have?
Twist Bioscience Corp has 65,832,420 shares outstanding.
What happened to Twist Bioscience Corp’s price movement after its last earnings report?
Twist Bioscience Corp reported an EPS of -€0.485 in its last earnings report, missing expectations of -€0.438. Following the earnings report the stock price went down -10.04%.
Which hedge fund is a major shareholder of Twist Bioscience Corp?
Currently, no hedge funds are holding shares in DE:0ME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Twist Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€95.90 (20.33% Upside)
€95.90 (20.33% Upside)
Blogger Sentiment
Neutral
DE:0ME Sentiment 70%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth €2.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.48%
Trailing 12-Months
Company Description
Twist Bioscience Corp
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
0ME Company Deck
0ME Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.View all DE:0ME earnings summaries0ME Stock 12 Month Forecast
Average Price Target
€95.90
▲(20.33% Upside)